The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Edwards Lifesciences's revenues will increase 12.9% and EPS will grow 43.4%.
The average estimate for revenue is $518.6 million. On the bottom line, the average EPS estimate is $0.76.
Last quarter, Edwards Lifesciences reported revenue of $510.5 million. GAAP reported sales were 19% higher than the prior-year quarter's $430.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.90. GAAP EPS of $0.77 for Q4 were 45% higher than the prior-year quarter's $0.53 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 75.4%, 320 basis points better than the prior-year quarter. Operating margin was 25.9%, 580 basis points better than the prior-year quarter. Net margin was 17.8%, 310 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $2.13 billion. The average EPS estimate is $3.28.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 148 members out of 201 rating the stock outperform, and 53 members rating it underperform. Among 59 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Edwards Lifesciences a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is outperform, with an average price target of $95.05.
Is Edwards Lifesciences the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Edwards Lifesciences to My Watchlist.